Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Luminex

Biotech & Life Sciences · Austin, United States · Founded 1995 Unicorn

We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, flow cytometry and imaging, genomic and proteomic research, and food safety

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Revenue
$500M–1B
Latest reported FY
Unlock exact value
Headcount
500–1k
Current team size
Unlock exact value

Global footprint

Where Luminex has talent and traffic

Workforce by country
16 countries with
team presence
🇺🇸 United States82.4%
🇨🇦 Canada7.7%
🇳🇱 Netherlands2.6%
🇨🇳 China2.3%
🇬🇧 United Kingdom1.3%
Top 5 of 16 shown

Patent intelligence

$161M patent portfolio · 75 active families

Estimated portfolio value
$161M
9.0% of valuation · 16.9× smaller than top peer Illumina ($2.7B)
75 active patent families
Where Luminex innovates BioinformaticsMolecular biologyNucleic acidBiologyOligonucleotide

Where Luminex concentrates vs peers

Each axis is a top-10 topic across Luminex and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Luminex's 3 investments and acquisitions.

Every disclosed deal where Luminex appeared as a backer or acquirer, 2011–2017. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Luminex's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Luminex deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Luminex's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Luminex

        An AI-synthesized read of the highest-engagement posts about Luminex on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Luminex on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.